Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers.

The current gold standard to reduce non-specific cellular uptake of drug delivery vehicles is by covalent attachment of poly(ethylene glycol) (PEG). It is thought that PEG can reduce protein adsorption and thereby confer a stealth effect. Here, we show that polystyrene nanocarriers that have been modified with PEG or poly(ethyl ethylene phosphate) (PEEP) and exposed to plasma proteins exhibit a low cellular uptake, whereas those not exposed to plasma proteins show high non-specific uptake. Mass spectrometric analysis revealed that exposed nanocarriers formed a protein corona that contains an abundance of clusterin proteins (also known as apolipoprotein J). When the polymer-modified nanocarriers were incubated with clusterin, non-specific cellular uptake could be reduced. Our results show that in addition to reducing protein adsorption, PEG, and now PEEPs, can affect the composition of the protein corona that forms around nanocarriers, and the presence of distinct proteins is necessary to prevent non-specific cellular uptake.

[1]  K. Landfester,et al.  Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. , 2015, Biomaterials.

[2]  Andrew Emili,et al.  Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.

[3]  S. Moghimi,et al.  Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. , 2008, Molecular immunology.

[4]  J. Rühe,et al.  Protein-resistant polymer surfaces , 2012 .

[5]  Giulio Caracciolo,et al.  Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. , 2013, Langmuir : the ACS journal of surfaces and colloids.

[6]  K. Blennow,et al.  Clusterin in cerebrospinal fluid: Analysis of carbohydrates and quantification of native and glycosylated forms , 2006, Neurochemistry International.

[7]  J. Tschopp,et al.  Clusterin: the intriguing guises of a widely expressed glycoprotein. , 1992, Trends in biochemical sciences.

[8]  F. Wurm,et al.  Water-Soluble Poly(phosphonate)s via Living Ring-Opening Polymerization. , 2014, ACS macro letters.

[9]  K. Landfester,et al.  Preparation of Fluorescent Carboxyl and Amino Functionalized Polystyrene Particles by Miniemulsion Polymerization as Markers for Cells , 2005 .

[10]  C. Libert,et al.  Protein modification and maintenance systems as biomarkers of ageing , 2015, Mechanisms of Ageing and Development.

[11]  J. Carver,et al.  Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. , 2000, Biochemistry.

[12]  D. Donadio,et al.  Hyperbranched unsaturated polyphosphates as a protective matrix for long-term photon upconversion in air. , 2014, Journal of the American Chemical Society.

[13]  Yen Wei,et al.  Core–shell structural iron oxide hybrid nanoparticles: from controlled synthesis to biomedical applications , 2011 .

[14]  Warren C. W. Chan,et al.  Understanding and Controlling the Interaction of Nanomaterials with Proteins in a Physiological Environment , 2012 .

[15]  P. Couvreur,et al.  Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2‐DE, CE and Protein Lab‐on‐chip® system , 2007, Electrophoresis.

[16]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[17]  Yoon Yeo,et al.  Recent advances in stealth coating of nanoparticle drug delivery systems. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[18]  Stefan Tenzer,et al.  Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. , 2015, Biomacromolecules.

[19]  R. Müller,et al.  Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. , 2005, International journal of pharmaceutics.

[20]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[21]  Jin-Zhi Du,et al.  Recent progress in polyphosphoesters: from controlled synthesis to biomedical applications. , 2009, Macromolecular bioscience.

[22]  Wolfgang J. Parak,et al.  Protein corona formation around nanoparticles – from the past to the future , 2014 .

[23]  K. Landfester,et al.  Nanocapsules with specific targeting and release properties using miniemulsion polymerization , 2013, Expert opinion on drug delivery.

[24]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[25]  R. Müller,et al.  Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. , 2000, International journal of pharmaceutics.

[26]  K. Landfester,et al.  Suppressing unspecific cell uptake for targeted delivery using hydroxyethyl starch nanocapsules. , 2012, Biomacromolecules.

[27]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[28]  O. Blaschuk,et al.  Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. , 1983, The Journal of biological chemistry.

[29]  Stefan Tenzer,et al.  Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. , 2011, ACS nano.

[30]  D. Begley,et al.  Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[32]  A. Baas,et al.  FDA-approved poly(ethylene glycol)–protein conjugate drugs , 2011 .

[33]  Shigenoki Kuga.  Pore size distribution analysis of gel substances by size exclusion chromatography , 1981 .

[34]  F. Wurm,et al.  Poly(phosphoester)s: A New Platform for Degradable Polymers. , 2015, Angewandte Chemie.

[35]  D. Hochstrasser,et al.  Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface‐modified latex particles evaluated by two‐dimensional polyacrylamide gel electrophoresis , 1993, Electrophoresis.

[36]  Amolkumar Karwa,et al.  Poly(ethylene oxide)-block-polyphosphester-based Paclitaxel Conjugates as a Platform for Ultra-high Paclitaxel-loaded Multifunctional Nanoparticles. , 2013, Chemical science.

[37]  T. Ishida,et al.  Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Nunzio Bottini,et al.  Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. , 2013, ACS nano.

[39]  Kazunori Kataoka,et al.  PEGylated Nanoparticles for Biological and Pharmaceutical Applications , 2003 .

[40]  L. Minthon,et al.  No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease , 2012, PloS one.

[41]  J. Kreuter,et al.  Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[42]  T. Koltai.  Clusterin: a key player in cancer chemoresistance and its inhibition , 2014, OncoTargets and therapy.

[43]  T. Ishida,et al.  Anti-polyethyleneglycol antibody response to PEGylated substances. , 2013, Biological & pharmaceutical bulletin.

[44]  Nicolas Bertrand,et al.  The journey of a drug-carrier in the body: an anatomo-physiological perspective. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[45]  H. Merkle,et al.  Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. , 2003, Biomaterials.

[46]  K. Landfester,et al.  Complementary analysis of the hard and soft protein corona: sample preparation critically effects corona composition. , 2015, Nanoscale.

[47]  En-Wei Lin,et al.  Therapeutic protein-polymer conjugates: advancing beyond PEGylation. , 2014, Journal of the American Chemical Society.

[48]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[49]  N. Adkinson,et al.  Hypersensitivity to Polyethylene Glycols , 2013, Journal of clinical pharmacology.

[50]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.